<DOC>
	<DOCNO>NCT02771795</DOCNO>
	<brief_summary>A Long-term Follow-up Study Cardiac Safety Patients HER2 Positive Early Locally Advanced Breast Cancer Who Have Completed SB3-G31-BC</brief_summary>
	<brief_title>A Long-term Follow-up Study Cardiac Safety Patients With HER2 ( + ) Breast Cancer Who Have Completed SB3-G31-BC</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Subjects complete study treatment SB3G31BC . Subjects must provide informed consent . Subjects unwilling follow study requirement eligible study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>HER2</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Biosimilar</keyword>
	<keyword>Cancer</keyword>
	<keyword>Breast</keyword>
	<keyword>Positive</keyword>
</DOC>